
Zai Lab Ltd
ZLABHealthcare|Biotechnology|China
$20.49
+0.52 (+2.60%)
Tangible Book
$5.25
Analyst Estimates
annual
{
"date": [
"202612",
"202712",
"202812",
"202912",
"203012"
],
"revenue_estimate": [
437.58,
561.76,
773.97,
991.35,
1263.55
],
"ebit_estimate": [
-266.12,
-204.24,
-93.47,
120.9,
208.65
],
"ebitda_estimate": [
-248.6,
-194.17,
-68.89,
null,
null
],
"net_income_estimate": [
-240.56,
-185.97,
-77.28,
105.2,
232
],
"per_share_eps_estimate": [
-2.26,
-1.79,
-0.83,
0.95,
2.1
],
"eps_nri_estimate": [
-2.21,
-1.7,
-0.72,
0.95,
2.1
],
"dividend_estimate": [
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
4.75,
4.42,
4.47,
null,
null
],
"pretax_income_estimate": [
-244.65,
-185.96,
-53.01,
134.8,
297.5
],
"operating_cash_flow_per_share_estimate": [
-1.65,
-1.48,
0.01,
null,
null
],
"roa_estimate": [
-26.18,
-22.78,
-16.7,
null,
null
],
"roe_estimate": [
-40.37,
-39.23,
-15.66,
null,
null
],
"gross_margin_estimate": [
61.27,
63.36,
72,
null,
null
],
"operating_cash_flow_estimate": [
-182.35,
-163.53,
1.11,
null,
null
],
"pettm_estimate": [
0,
0,
0,
21.57,
9.76
],
"long_term_growth_rate_mean": 23.23,
"long_term_revenue_growth_rate_mean": "19.84",
"future_per_share_eps_estimate_growth": 19.67,
"future_eps_nri_estimate_growth": 23.23,
"future_revenue_estimate_growth": 19.84,
"future_ebit_estimate_growth": 25.61,
"future_ebitda_estimate_growth": 30.61,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": 23.81,
"future_pretax_income_estimate_growth": 32.4,
"future_book_value_per_share_estimate_growth": -11.15,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": 6.8,
"future_operating_cash_flow_per_share_estimate_growth": null
}
quarterly
{
"date": [
"202606",
"202609",
"202612",
"202703",
"202706",
"202709",
"202712"
],
"revenue_estimate": [
103.95,
110.77,
118.99,
132,
143.4,
152.2,
165
],
"ebit_estimate": [
-67.17,
-61.99,
-61.85,
-59.1,
-54.3,
-50.5,
-43.1
],
"ebitda_estimate": [
-63.13,
-57.16,
-57.32,
null,
null,
null,
null
],
"net_income_estimate": [
-72.83,
-59.33,
-57.89,
-54.5,
-49.7,
-45.9,
-38.6
],
"per_share_eps_estimate": [
-0.57,
-0.52,
-0.5,
-0.49,
-0.45,
-0.41,
-0.35
],
"eps_nri_estimate": [
-0.6,
-0.53,
-0.53,
-0.49,
-0.45,
-0.41,
-0.35
],
"dividend_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
5.57,
5.18,
4.82,
null,
null,
null,
null
],
"pretax_income_estimate": [
-63.79,
-59.33,
-57.89,
-54.5,
-49.7,
-45.9,
-38.6
],
"operating_cash_flow_per_share_estimate": [
-0.49,
-0.48,
-0.44,
null,
null,
null,
null
],
"roa_estimate": [
null,
null,
2.7,
null,
null,
null,
null
],
"roe_estimate": [
-36.78,
-39.73,
-42.76,
null,
null,
null,
null
],
"gross_margin_estimate": [
60,
60,
60,
null,
null,
null,
null
],
"operating_cash_flow_estimate": [
-54.26,
-53.16,
-48.73,
null,
null,
null,
null
],
"pettm_estimate": [
0,
0,
0,
0,
null,
null,
null
],
"long_term_growth_rate_mean": 23.23,
"long_term_revenue_growth_rate_mean": "19.84",
"future_per_share_eps_estimate_growth": 19.67,
"future_eps_nri_estimate_growth": 23.23,
"future_revenue_estimate_growth": 19.84,
"future_ebit_estimate_growth": 25.61,
"future_ebitda_estimate_growth": 30.61,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": 23.81,
"future_pretax_income_estimate_growth": 32.4,
"future_book_value_per_share_estimate_growth": -11.15,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": 6.8,
"future_operating_cash_flow_per_share_estimate_growth": null
}